{"id":"rabies-vaccine-manufactured-by-chengda","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Myalgia"},{"rate":"5-10","effect":"Fever"},{"rate":"1-5","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rabies vaccines contain inactivated or attenuated rabies virus antigens that trigger both humoral (antibody) and cell-mediated immune responses. This allows the body to recognize and neutralize rabies virus before it reaches the central nervous system, which is critical since rabies is nearly 100% fatal once clinical symptoms appear. The vaccine is typically administered post-exposure in combination with rabies immunoglobulin for maximum efficacy.","oneSentence":"The rabies vaccine stimulates the immune system to produce antibodies and cellular immunity against the rabies virus, preventing infection after exposure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:40.871Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Post-exposure prophylaxis of rabies virus infection"},{"name":"Pre-exposure prophylaxis for high-risk individuals (veterinarians, laboratory workers, travelers to endemic areas)"}]},"trialDetails":[{"nctId":"NCT01173302","phase":"PHASE4","title":"Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2010-05","conditions":"Rabies","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ChengDa Speeda"],"phase":"marketed","status":"active","brandName":"Rabies vaccine, manufactured by ChengDa","genericName":"Rabies vaccine, manufactured by ChengDa","companyName":"Peking University People's Hospital","companyId":"peking-university-people-s-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"The rabies vaccine stimulates the immune system to produce antibodies and cellular immunity against the rabies virus, preventing infection after exposure. Used for Post-exposure prophylaxis of rabies virus infection, Pre-exposure prophylaxis for high-risk individuals (veterinarians, laboratory workers, travelers to endemic areas).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}